Skip to main content
. 2022 Dec 1;23:438–470. doi: 10.1016/j.bioactmat.2022.11.014

Fig. 2.

Fig. 2

A timeline of key milestones in the development of mRNA technology and nano-mRNA formulations in preclinical and clinical studies, of which targeted cancer immunotherapy related are highlighted with orange outlines.